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Ectopic adrenocorticotropic hormone (ACTH) syndrome
accounts for 10%–20% of the cases of ACTH-dependent
Cushing’s syndrome (1). Ectopic ACTH secretion typically
results from an occult, slow-growing bronchial carcinoid
tumor. The diagnosis of these relatively small tumors can be
difficult with conventional imaging procedures, such as
computerized tomography (CT) or magnetic resonance
imaging (MRI) (2). Herein, we present a case of ectopic
ACTH syndrome arising from a bronchial carcinoid tumor
that was diagnosed with somatostatin receptor scintigraphy
(SRS).
CASE DESCRIPTION
A 25-year-old Caucasian woman was admitted for
oligomenorrhea and hirsutism. A physical examination
revealed central obesity, a ‘‘buffalo hump’’, acne, and severe
hirsutism (Ferriman-Gallwey score of 18). After overnight
dexamethasone suppression testing (DST), her serum cortisol
level was 14.4 mg/dL. She was hospitalized with a presump-
tive diagnosis of Cushing’s syndrome.
Her diurnal cortisol secretion rhythm was found to be
impaired; her serum cortisol level at midnight was 27.1 mg/
dL. Low-dose DST was also consistent with this diagnosis,
with an unsuppressed serum cortisol level of 4.2 mg/dL.
Her basal ACTH and cortisol levels were 67 pg/mL and
15.2 mg/dL, respectively.
With a refined presumptive diagnosis of ACTH-depen-
dent Cushing’s syndrome, we performed overnight high-
dose DST with 8 mg dexamethasone. Her serum cortisol
level was 10 mg/dL, revealing a lack of suppression. An
MRI revealed a 3-mm microadenoma of the hypophysis.
However, inferior petrosal sinus sampling (IPSS) revealed
no substantial gradient in ACTH levels between the center
and the periphery (Table 1). Thus, a diagnosis of ectopic
Cushing’s syndrome was proposed.
Upon CT of the thorax and abdomen, we noted a contrast-
enhancing small lesion at the left posterobasal segment
(Figure 1). No involvement was present upon positron
emission tomography (PET). SRS revealed a lesion at the left
posterobasal segment consistent with the thorax CT,
suggesting a bronchial carcinoid tumor (Figure 2).
The patient underwent segmentectomy. An immunohis-
tochemical evaluation revealed positive staining for chro-
mogranin, synaptophysin, and ACTH (Figure 3). Two
weeks after surgery, cortisol was suppressed upon low-
dose DST (serum cortisol level, 0.2 mg/dL). After four
months of follow up, she had lost 15 kg, her menstrual
periods had become regular, and her acne and hirsutism
had regressed significantly.
DISCUSSION
Ectopic ACTH syndrome represents a minority of all cases
of Cushing’s syndrome (1,2). High-dose DST can be used to
discriminate ectopic ACTH syndrome from classic Cushing’s
disease; a suppression of more than 50% of the basal cortisol
level can be observed in more than 80% of patients with
Cushing’s disease (3). However, the diagnostic utility of high-
dose DST is limited, and this test is not recommended when
IPSS is available (3). In our patient, although cortisol
suppression could be compatible with a diagnosis of ectopic
ACTH syndrome, she also had a microadenoma in the
hypophysis. Because adenomas are incidentally discovered
in up to 10% of the normal population, IPSS is advised for
patients with ACTH-dependent Cushing’s syndrome and a
hypophyseal adenoma smaller than 6 mm, particularly when
test results conflict (4).
IPSS can demonstrate the ratio of the ACTH level in the
central sinus relative to the peripheral sinus. A central/
peripheral ratio of 2 before the administration of cortico-
tropin-releasing hormone and a ratio of $3 after its
administration strongly suggests Cushing’s disease (5).
However, although a positive result is highly suggestive
of Cushing’s disease, false-negative results might be more
common than previously appreciated (2%–4%). In cases of a
negative response, clinicians should perform a careful
search for an ectopic source (6). In our patient, although
she had a pituitary microadenoma (3 mm), the results of
high-dose DST and IPSS were consistent with ectopic ACTH
syndrome.
The source of ectopic ACTH secretion should be estab-
lished after diagnosis because the excision of an ACTH-
producing tumor can be curative (2,7). The most likely site of
ACTH-producing tumors is the thorax, and these tumors are
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Table 1 - Adrenocorticotropic hormone (ACTH) levels in





5 minutes 141 163 151
2 minutes 144 159 164
Time after infusion
2 minutes 148 160 151
5 minutes 149 166 181
10 minutes 160 175 172 Figure 1 - Computerized tomography of the bronchial carcinoid.
Figure 2 - Somatostatin receptor scintigraphy of the bronchial carcinoid.
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frequently bronchial carcinoid tumors. Locating these tumors
can be challenging; they are relatively small and slow-
growing, and conventional imaging studies, such as CT and
MRI, identify the tumor in only 50% of cases (2,4,7). The
tumor can remain occult long after the diagnosis of Cushing’s
syndrome (4).
Functional imaging studies, such as PET and SRS, are
complementary imaging tools for revealing the presence of
carcinoids (6). SRS might be superior to PET in detecting
bronchial carcinoids. Although PET can detect highly active
proliferative tumors, bronchial carcinoids usually have a
low proliferation index and are slow growing, quite small
lesions (7,8). However, the success of SRS depends only on
the presence of somatostatin receptors, which have been
identified on many cells of neuroendocrine origin (8). The
radiolabelled somatostatin analog octreotide can bind to
somatostatin receptors 2 and 5 with high affinity (8).
Bronchial carcinoids express both receptors. Nevertheless,
these tumors may show heterogeneity in the degree of
somatostatin receptor expression (8).
The diagnostic sensitivity of SRS is approximately 25%–
73% for the detection of an ectopic source of ACTH
secretion (9). Ilias and colleagues reported that the sensitiv-
ity of SRS is only approximately 49%, and it is insufficient
for lesions that are not present on CT or MRI (1). Zemskova
and colleagues reported a 57% sensitivity and a 79%
positive predictive value for SRS for detecting ectopic
ACTH-producing tumors (7).
The use of a single imaging tool may not be sufficient to
diagnose ectopic ACTH-secreting tumors; conventional and
functional imaging studies should be used in combination
when needed (2,6-9). In our case, the ectopic lesion was
shown onCT but not on PET. SRS confirmed the lesion shown
on CT, and the tumor was extracted. Suppression by DST
revealed biochemical recruitment, and ACTH staining of the
excised tissue confirmed the ectopic tumor postoperatively.
In conclusion, in cases of ectopic ACTH syndrome, the
exact location of the lesion is needed for a curative approach.
Conventional imaging studies may not always show the
lesion. The use of somatostatin receptor scintigraphy in
addition to conventional imaging may help localize lesions.
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Figure 3 - A) ACTH staining of bronchial cells. B) Vascular invasion by tumor cells. C) Lymphoid invasion by tumor cells.
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